Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic markers in prostate cancer.

Jeffrey S Ross1, Christine E Sheehan, Hugh A G Fisher

  • 1Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA. rossj@mail.amc.edu

Expert Review of Molecular Diagnostics
|April 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Multi-Gene Signature Associated with 1-Year Survival in Patients with Stage I Liver Cancer: Integration of Preclinical and TCGA Data.

Current issues in molecular biology·2026
Same author

cGAS/STING Pathway Mediates Accelerated Intestinal Cell Senescence and SASP After GCR Exposure in Mice.

Cells·2025
Same author

Reply by Authors.

The Journal of urology·2025
Same author

Participant-Reported Outcome Measures After Transrectal and Transperineal Prostate Biopsy in a Randomized Clinical Trial.

The Journal of urology·2025
Same author

Senolytic agent ABT-263 mitigates low- and high-LET radiation-induced gastrointestinal cancer development in <i>Apc</i><sup>1638N/+</sup> mice.

Aging·2025
Same author

Effects of High-Linear-Energy-Transfer Heavy Ion Radiation on Intestinal Stem Cells: Implications for Gut Health and Tumorigenesis.

Cancers·2024

This review compares established and emerging biomarkers for predicting prostate cancer prognosis. It assesses their clinical utility and validation status, aiding in treatment decisions.

Area of Science:

  • Oncology
  • Biomarker Research
  • Prognostic Factor Analysis

Background:

  • Prostate cancer prognosis relies on accurate prognostic factors.
  • Existing biomarkers vary in clinical adoption and validation.
  • New molecular assays offer potential for improved prediction.

Purpose of the Study:

  • To evaluate ancillary biomarkers and molecular assays for prostate cancer prognosis.
  • To compare Category I, II, and III prognostic factors.
  • To assess the clinical readiness of emerging prostate cancer tests.

Main Methods:

  • Review of documented ancillary biomarkers.
  • Evaluation of emerging molecular assays.
  • Comparison of prognostic factors based on validation status (Category I, II, III).

Related Experiment Videos

Main Results:

  • Established biomarkers (Category I) are widely used.
  • Newer tests (Category II) are entering clinical practice.
  • Emerging molecular assays (Category III) require further validation.

Conclusions:

  • Biomarker selection for prostate cancer prognosis is evolving.
  • Understanding validation status is crucial for clinical application.
  • Further research is needed for emerging molecular assays.